Clinical relevance of intraoperative pleural lavage cytology in non-small cell lung cancer.
Clinical relevance of intraoperative pleural lavage cytology in non-small cell lung cancer.
复制标题
非小细胞肺癌术中胸腔灌洗细胞学的临床意义。
DOI:
10.1016/j.athoracsur.2006.07.035
复制
发表时间:
2007
期刊:
影响因子:
--
通讯作者:
Kotaro Kameyama
中科院分区:
文献类型:
--
作者:
T. Nakagawa;N. Okumura;Yujiro Kokado;K. Miyoshi;Tomoaki Matsuoka;Kotaro Kameyama
BACKGROUNDIntraoperative pleural lavage cytology for patients with lung cancer has been reported to be useful in detecting subclinical pleural dissemination. However, this procedure is not necessary for the staging of lung cancer in the current TNM staging system.METHODSClinical records of 1025 patients with non-small cell lung cancer who underwent surgery were retrospectively reviewed and evaluated for the clinical relevance of intraoperative pleural lavage cytology.RESULTSSpecimens of 37 patients (3.6%) were positive for pleural lavage cytology (PLC). Patients were categorized into three groups: positive PLC group, 27 patients with positive PLC without malignant pleural effusion or pleural dissemination; pleural dissemination (PD) group, 21 patients with malignant pleural effusion or PD; negative PLC group, 977 patients with negative PLC or negative PLC without PD. The positive PLC group had a significantly higher ratio of adenocarcinomas than the negative PLC group (p = 0.014). There was a significant difference in distribution of pleural factors between the positive and negative PLC groups (p < 0.001). Survival in the positive PLC group was significantly worse than in the negative PLC group (p = 0.007), especially in pathologic stage I (p = 0.001), but significantly better than in the PD group (p = 0.038). PLC status was found to be a significant independent prognostic factor in the multivariate analysis (p = 0.016).CONCLUSIONSThe present study demonstrates the clinical relevance of intraoperative PLC in early stage non-small cell lung cancer. The result of intraoperative PLC should be involved in the staging system of lung cancer.